Tech News
← Back to articles

This Common Heart Attack Drug May Actually Be Worthless for Most People

read original related products more articles

A common treatment given after heart attacks may not be worthwhile for a large segment of the population. New trial data finds that most people who suffer a heart attack do not benefit from taking beta-blockers afterward.

A large international team of researchers conducted the trial, which compared the outcomes of nearly 10,000 heart attack patients who were either given beta-blocker therapy or not.

“This trial will reshape all international clinical guidelines.’

On average, people with preserved heart function given beta-blockers were no less likely to die or to experience a second heart attack than those not given beta-blockers, the researchers found. Secondary data also showed that women might actually face a higher risk of complications from taking these medications.

“This trial will reshape all international clinical guidelines,” said senior study author Valentin Fuster, president of Mount Sinai Fuster Heart Hospital, in a statement from Mount Sinai.

Why doctors use beta-blockers

For more than 40 years, beta-blockers have been a key aspect of treating and managing cardiovascular disease. These drugs block the effects of adrenaline on the body’s beta-receptors, which then reduces heart rate and lowers blood pressure (among other bodily changes). They’re often used to reduce stress on a badly damaged heart following a heart attack (myocardial infarction), in theory lowering the risk of a second heart attack or other cardiovascular issues.

But heart medicine has evolved greatly since the arrival of the first beta-blockers in the 1960s. New treatments and improved knowledge have made it easier for doctors to prevent these infarctions from causing as much damage to the heart as before. And that’s led some researchers to wonder whether beta-blockers should still be considered a front-line treatment following heart attacks, including the team behind this large new trial.

A therapy in need of a reboot

The team’s trial, named REBOOT, involved roughly 8,500 people. The patients had all experienced relatively mild heart attacks and appeared to have a left ventricular ejection fraction (LVEF) above 40%. LVEF measures how well our left ventricle (the main pumping chamber) pumps out blood. A healthy LVEF is typically considered above 51%, while slightly reduced function is between 40% and 50%.

... continue reading